These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25151225)

  • 1. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
    Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
    Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
    Satti I; Marshall JL; Harris SA; Wittenberg R; Tanner R; Lopez Ramon R; Wilkie M; Ramos Lopez F; Riste M; Wright D; Peralta Alvarez MP; Williams N; Morrison H; Stylianou E; Folegatti P; Jenkin D; Vermaak S; Rask L; Cabrera Puig I; Powell Doherty R; Lawrie A; Moss P; Hinks T; Bettinson H; McShane H
    Lancet Infect Dis; 2024 Aug; 24(8):909-921. PubMed ID: 38621405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
    Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
    Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
    Audran R; Karoui O; Donnet L; Soumas V; Fares F; Lovis A; Noirez L; Cavassini M; Fayet-Mello A; Satti I; McShane H; Spertini F
    J Infect; 2024 Aug; 89(2):106205. PubMed ID: 38897242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
    Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
    Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
    White AD; Sibley L; Dennis MJ; Gooch K; Betts G; Edwards N; Reyes-Sandoval A; Carroll MW; Williams A; Marsh PD; McShane H; Sharpe SA
    Clin Vaccine Immunol; 2013 May; 20(5):663-72. PubMed ID: 23446219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
    Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
    Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
    Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
    Minhinnick A; Satti I; Harris S; Wilkie M; Sheehan S; Stockdale L; Manjaly Thomas ZR; Lopez-Ramon R; Poulton I; Lawrie A; Vermaak S; Le Vert A; Del Campo J; Hill F; Moss P; McShane H
    Vaccine; 2016 Mar; 34(11):1412-21. PubMed ID: 26854906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
    Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
    PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
    Meyer J; Harris SA; Satti I; Poulton ID; Poyntz HC; Tanner R; Rowland R; Griffiths KL; Fletcher HA; McShane H
    Vaccine; 2013 Feb; 31(7):1026-33. PubMed ID: 23266342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
    Wajja A; Kizito D; Nassanga B; Nalwoga A; Kabagenyi J; Kimuda S; Galiwango R; Mutonyi G; Vermaak S; Satti I; Verweij J; Tukahebwa E; Cose S; Levin J; Kaleebu P; Elliott AM; McShane H
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005440. PubMed ID: 28472067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
    Pathan AA; Minassian AM; Sander CR; Rowland R; Porter DW; Poulton ID; Hill AV; Fletcher HA; McShane H
    Vaccine; 2012 Aug; 30(38):5616-24. PubMed ID: 22789508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
    Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
    Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
    Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M;
    Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
    von Reyn CF; Lahey T; Arbeit RD; Landry B; Kailani L; Adams LV; Haynes BC; Mackenzie T; Wieland-Alter W; Connor RI; Tvaroha S; Hokey DA; Ginsberg AM; Waddell R
    PLoS One; 2017; 12(5):e0175215. PubMed ID: 28498853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans.
    Jeyanathan M; Fritz DK; Afkhami S; Aguirre E; Howie KJ; Zganiacz A; Dvorkin-Gheva A; Thompson MR; Silver RF; Cusack RP; Lichty BD; O'Byrne PM; Kolb M; Medina MFC; Dolovich MB; Satia I; Gauvreau GM; Xing Z; Smaill F
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34990408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.